These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689 [TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Sibley K; Cuthbert-Heavens D; Knowles MA Oncogene; 2001 Feb; 20(6):686-91. PubMed ID: 11314002 [TBL] [Abstract][Full Text] [Related]
5. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Billerey C; Chopin D; Aubriot-Lorton MH; Ricol D; Gil Diez de Medina S; Van Rhijn B; Bralet MP; Lefrere-Belda MA; Lahaye JB; Abbou CC; Bonaventure J; Zafrani ES; van der Kwast T; Thiery JP; Radvanyi F Am J Pathol; 2001 Jun; 158(6):1955-9. PubMed ID: 11395371 [TBL] [Abstract][Full Text] [Related]
6. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Bakkar AA; Wallerand H; Radvanyi F; Lahaye JB; Pissard S; Lecerf L; Kouyoumdjian JC; Abbou CC; Pairon JC; Jaurand MC; Thiery JP; Chopin DK; de Medina SG Cancer Res; 2003 Dec; 63(23):8108-12. PubMed ID: 14678961 [TBL] [Abstract][Full Text] [Related]
7. Frequent FGFR3 mutations in urothelial papilloma. van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885 [TBL] [Abstract][Full Text] [Related]
8. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143 [TBL] [Abstract][Full Text] [Related]
9. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601 [TBL] [Abstract][Full Text] [Related]
10. G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia. Katsumata N; Kuno T; Miyazaki S; Mikami S; Nagashima-Miyokawa A; Nimura A; Horikawa R; Tanaka T Endocr J; 1998 Apr; 45 Suppl():S171-4. PubMed ID: 9790257 [TBL] [Abstract][Full Text] [Related]
12. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Rieger-Christ KM; Mourtzinos A; Lee PJ; Zagha RM; Cain J; Silverman M; Libertino JA; Summerhayes IC Cancer; 2003 Aug; 98(4):737-44. PubMed ID: 12910517 [TBL] [Abstract][Full Text] [Related]
13. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine. Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367 [TBL] [Abstract][Full Text] [Related]
14. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. van Rhijn BW; van der Kwast TH; Vis AN; Kirkels WJ; Boevé ER; Jöbsis AC; Zwarthoff EC Cancer Res; 2004 Mar; 64(6):1911-4. PubMed ID: 15026322 [TBL] [Abstract][Full Text] [Related]
15. Improved diagnosis of a common mutation (R248C) in the human growth factor receptor 3 (FGFR3) gene that causes type I Thanatophoric dysplasia. Simsek M; Al-Gazali L; Al-Mjeni R; Bayoumi R Clin Biochem; 2003 Mar; 36(2):151-3. PubMed ID: 12633765 [No Abstract] [Full Text] [Related]
16. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828 [TBL] [Abstract][Full Text] [Related]
17. Thanatophoric dysplasia type I with syndactyly. Brodie SG; Kitoh H; Lipson M; Sifry-Platt M; Wilcox WR Am J Med Genet; 1998 Nov; 80(3):260-2. PubMed ID: 9843049 [TBL] [Abstract][Full Text] [Related]
18. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. van Rhijn BW; Lurkin I; Radvanyi F; Kirkels WJ; van der Kwast TH; Zwarthoff EC Cancer Res; 2001 Feb; 61(4):1265-8. PubMed ID: 11245416 [TBL] [Abstract][Full Text] [Related]
19. No evidence of somatic FGFR3 mutation in various types of carcinoma. Karoui M; Hofmann-Radvanyi H; Zimmermann U; Couvelard A; Degott C; Faridoni-Laurens L; Ahomadegbe JC; Gazzeri S; Brambilla E; Clerici T; Charbonnier P; Tresallet C; Mitry E; Penna C; Rougier P; Boileau C; Thiery JP; Nordlinger B; Franc B; Radvanyi F Oncogene; 2001 Aug; 20(36):5059-61. PubMed ID: 11526491 [TBL] [Abstract][Full Text] [Related]
20. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]